Profile data is unavailable for this security.
About the company
PepGen Inc. is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies. The Company’s Enhanced Delivery Oligonucleotide (EDO) platform leverages cell-penetrating peptides to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake and nuclear delivery. Using these EDO peptides, the Company is generating a pipeline of oligonucleotide therapeutic candidates designed to target the root cause of serious diseases. It is focused on addressing the underlying cause of Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1), which have high unmet need. Its pipeline consists of two clinical stage programs, PGN-EDO51 for DMD patients who are amenable to an exon 51-skipping approach and PGN-EDODM1 for DM1 patients, and several additional preclinical stage programs. Its product candidates also include PGN-EDO53, PGN-EDO45 and PGN-EDO44.
- Revenue in USD (TTM)0.00
- Net income in USD-93.56m
- Incorporated2020
- Employees81.00
- LocationPepGen Inc245 Main St, 2nd FloorCAMBRIDGE 02142United StatesUSA
- Phone+1 (703) 456-8000
- Fax+1 (302) 655-5049
- Websitehttps://pepgen.com
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Armata Pharmaceuticals Inc | 5.05m | -46.90m | 413.58m | 60.00 | -- | -- | -- | 81.83 | -1.30 | -1.30 | 0.1396 | -2.64 | 0.0538 | -- | 3.39 | 84,233.34 | -49.96 | -47.36 | -- | -60.79 | -- | -- | -928.00 | -829.99 | -- | -2.12 | 2.88 | -- | 14.24 | -- | 72.60 | -- | 53.02 | -- |
| Immix Biopharma Inc | 0.00 | -23.56m | 425.05m | 18.00 | -- | 32.58 | -- | -- | -0.7742 | -0.7742 | 0.00 | 0.2502 | 0.00 | -- | -- | 0.00 | -104.21 | -108.46 | -169.47 | -146.18 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -40.11 | -- | 176.33 | -- |
| 4D Molecular Therapeutics Inc | 120.00k | -209.18m | 431.53m | 227.00 | -- | 1.07 | -- | 3,596.06 | -3.74 | -3.74 | 0.0022 | 7.89 | 0.0002 | -- | -- | 528.63 | -40.70 | -32.02 | -43.51 | -33.96 | -- | -- | -174,314.20 | -895.24 | -- | -- | 0.00 | -- | -99.82 | -64.94 | -59.53 | -- | 3.40 | -- |
| Anavex Life Sciences Corp | 0.00 | -39.95m | 434.63m | 34.00 | -- | 3.43 | -- | -- | -0.4649 | -0.4649 | 0.00 | 1.37 | 0.00 | -- | -- | 0.00 | -31.08 | -33.08 | -33.63 | -36.14 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -7.85 | -- | -- | -- |
| Lineage Cell Therapeutics Inc | 10.82m | -67.66m | 435.32m | 70.00 | -- | 19.75 | -- | 40.25 | -0.2955 | -0.2955 | 0.0469 | 0.0957 | 0.1162 | -- | 40.66 | 154,514.30 | -72.50 | -20.81 | -81.52 | -24.54 | 97.84 | 90.99 | -624.16 | -331.61 | -- | -- | 0.004 | -- | 6.19 | 22.00 | 13.39 | -- | 5.13 | -- |
| Verastem Inc | 13.38m | -241.11m | 438.24m | 78.00 | -- | -- | -- | 32.76 | -4.02 | -4.02 | 0.2209 | -0.2326 | 0.0882 | -- | 3.76 | 171,525.60 | -159.03 | -68.26 | -233.92 | -83.33 | 85.14 | -- | -1,802.12 | -417.53 | 2.55 | -- | 1.21 | -- | -- | -10.54 | -49.53 | -- | 31.95 | -- |
| Regenxbio Inc | 161.32m | -177.92m | 439.91m | 353.00 | -- | 2.72 | -- | 2.73 | -3.46 | -3.46 | 3.14 | 3.19 | 0.3089 | -- | 6.59 | 456,991.50 | -34.07 | -20.33 | -43.55 | -23.79 | 87.18 | 76.64 | -110.29 | -82.78 | -- | -6.74 | 0.5427 | -- | -7.66 | 18.79 | 13.81 | -- | -26.96 | -- |
| PepGen Inc | 0.00 | -93.56m | 441.36m | 81.00 | -- | 2.71 | -- | -- | -2.84 | -2.84 | 0.00 | 2.37 | 0.00 | -- | -- | 0.00 | -51.93 | -45.06 | -56.56 | -49.76 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -14.44 | -- | 76.52 | -- |
| Entrada Therapeutics Inc | 25.42m | -143.75m | 453.67m | 152.00 | -- | 1.48 | -- | 17.85 | -3.47 | -3.47 | 0.6145 | 8.00 | 0.0563 | -- | 10.47 | 167,243.40 | -31.81 | -13.07 | -34.24 | -15.14 | -- | -- | -565.48 | -63.14 | -- | -- | 0.00 | -- | -87.94 | -- | -319.04 | -- | -14.85 | -- |
| Assembly Biosciences Inc | 37.19m | -38.55m | 455.53m | 73.00 | -- | 2.49 | -- | 12.25 | -4.81 | -4.81 | 4.33 | 11.55 | 0.2186 | -- | 81.56 | 509,465.80 | -22.66 | -41.01 | -31.44 | -47.70 | -- | -- | -103.65 | -319.31 | -- | -- | 0.00 | -- | 298.16 | 12.31 | 34.38 | -- | -55.21 | -- |
| Tectonic Therapeutic Inc | 0.00 | -74.15m | 458.06m | 60.00 | -- | 1.82 | -- | -- | -4.04 | -4.04 | 0.00 | 13.41 | 0.00 | -- | -- | 0.00 | -35.83 | -- | -37.77 | -- | -- | -- | -- | -- | -- | -- | 0.0015 | -- | -- | -- | -27.89 | -- | -- | -- |
| Kyverna Therapeutics Inc | 0.00 | -160.99m | 458.16m | 129.00 | -- | 2.31 | -- | -- | -3.72 | -3.72 | 0.00 | 3.47 | 0.00 | -- | -- | 0.00 | -61.17 | -- | -69.77 | -- | -- | -- | -- | -- | -- | -- | 0.0013 | -- | -- | -- | -111.17 | -- | -- | -- |
| Vanda Pharmaceuticals Inc. | 216.11m | -220.47m | 463.41m | 533.00 | -- | 1.42 | -- | 2.14 | -3.74 | -3.74 | 3.67 | 5.54 | 0.3774 | 7.29 | 4.25 | 405,450.30 | -38.51 | -6.49 | -48.99 | -7.64 | 93.96 | 92.12 | -102.02 | -17.46 | 2.38 | -- | 0.0224 | -- | 8.72 | -2.73 | -1,066.53 | -- | -11.08 | -- |
| Solid Biosciences Inc | 0.00 | -167.14m | 464.35m | 100.00 | -- | 2.13 | -- | -- | -2.49 | -2.49 | 0.00 | 2.80 | 0.00 | -- | -- | 0.00 | -68.82 | -47.92 | -78.37 | -53.98 | -- | -- | -- | -2,151.47 | -- | -- | 0.0013 | -- | -- | -- | -29.87 | -- | -31.66 | -- |
| Adlai Nortye Ltd (ADR) | 0.00 | -42.59m | 468.09m | 123.00 | -- | 37.31 | -- | -- | -1.14 | -1.14 | 0.00 | 0.2147 | 0.00 | -- | -- | 0.00 | -47.40 | -- | -138.41 | -- | -- | -- | -- | -- | -- | -26.36 | 0.8491 | -- | -- | -- | 52.51 | -- | -- | -- |
| Altimmune Inc | 20.00k | -83.92m | 469.39m | 59.00 | -- | 2.14 | -- | 23,469.39 | -1.07 | -1.07 | 0.0003 | 1.94 | 0.0001 | -- | 0.0314 | 338.98 | -45.82 | -42.36 | -48.64 | -45.46 | -- | -- | -419,575.00 | -3,193.88 | -- | -- | 0.0722 | -- | -95.31 | -67.83 | -7.48 | -- | -- | -- |
Data as of Mar 03 2026. Currency figures normalised to PepGen Inc's reporting currency: US Dollar USD
57.49%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| RA Capital Management LPas of 31 Dec 2025 | 20.06m | 29.19% |
| Viking Global Investors LPas of 31 Dec 2025 | 3.48m | 5.07% |
| Commodore Capital LPas of 31 Dec 2025 | 3.40m | 4.95% |
| Point72 Asset Management LPas of 31 Dec 2025 | 2.27m | 3.31% |
| Laurion Capital Management LPas of 31 Dec 2025 | 2.05m | 2.99% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 1.94m | 2.82% |
| BVF Partners LPas of 31 Dec 2025 | 1.92m | 2.79% |
| Nantahala Capital Management LLCas of 31 Dec 2025 | 1.55m | 2.25% |
| Janus Henderson Investors US LLCas of 31 Dec 2025 | 1.50m | 2.18% |
| Pictet Asset Management SAas of 31 Dec 2025 | 1.35m | 1.97% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
